Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16899301 | 0.90 | ANPEP (0.55) | ANPEPKMT2AMEN1MAPTKDM4E | |
| SCHEMBL16908240 | 0.89 | CARM1 (0.60) | ANPEPKMT2AMEN1MAPTKDM4E | |
| SCHEMBL16899278 | 0.89 | CARM1 (0.60) | ANPEPKMT2AMEN1MAPTKDM4E | |
| SCHEMBL12863555 | 0.88 | ANPEP (0.56) | ANPEPKMT2AMEN1MAPTKDM4E | |
| SCHEMBL14108271 | 0.86 | ANPEP (0.55) | ANPEPKMT2AMEN1MAPTKDM4E | |
| SCHEMBL16908117 | 0.86 | ANPEP (0.55) | ANPEPKMT2AMEN1MAPTKDM4E | |
| SCHEMBL18812522 | 0.86 | ANPEP (0.55) | ANPEPKMT2AMEN1MAPTKDM4E | |
| SCHEMBL18787152 | 0.85 | ANPEP (0.57) | ANPEPKMT2AMEN1MAPTKDM4E | |
| SCHEMBL16899284 | 0.85 | ANPEP (0.57) | ANPEPKMT2AMEN1MAPTKDM4E | |
| SCHEMBL1566774 | 0.84 | MEN1 (0.64) | ANPEPKMT2AMEN1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218374-A1 | Nucleic Acid Compounds That Bind Coronavirus Proteins | SOMALOGIC OPERATING CO., INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240218374-A1 | Nucleic Acid Compounds That Bind Coronavirus Proteins | SOMALOGIC OPERATING CO., INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230193287-A1 | Nucleic Acid Compounds for Binding Growth Differentiation Factor 11 | SOMALOGIC OPERATING CO., INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-20230024434-A1 | Methods for Developing Personalized Drug Treatment Plans and Targeted Drug Development Based on Proteomic Profiles | SOMALOGIC, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-16 | — | — | US | disclosed |
| US-11111495-B2 | Method for generating aptamers with improved off-rates | SOMALOGIC, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-10544419-B2 | PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders | SOMALOGIC INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190330634-A1 | Method for Generating Aptamers with Improved Off-Rates | SOMALOGIC OPERATING CO., INC. | 2019-10-31 | — | — | US | disclosed |
| US-20110082286-A1 | Method for Generating Aptamers with Improved Off-Rates | SOMALOGIC, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082286-A1 | Method for Generating Aptamers with Improved Off-Rates | SOMALOGIC, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011006075-A1 | METHOD FOR GENERATING APTAMERS WITH IMPROVED OFF-RATES | SOMALOGIC, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-7855054-B2 | Multiplexed analyses of test samples | SOMALOGIC, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855054-B2 | Multiplexed analyses of test samples | SOMALOGIC, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7402690-B2 | Chain transfer agents for raft polymerization in aqueous media | UNIVERSITY OF SOUTHERN MISSISSIPPI (US) | 2008-07-22 | — | — | US | disclosed |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CAO JINGRONG | 2007-11-15 | — | — | US | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070123670-A1 | Chain transfer agents for raft polymerization in aqueous media | MCCORMICK CHARLES L | 2007-05-31 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAPKAPK2 | ANPEP 3964/4885KMT2A 2432/4885MEN1 2607/4885 |
| US-20230193287-A1 | Nucleic Acid Compounds for Binding Growth Differentiation Factor 11 | MSTN, S100A11, IGF2BP1 | ANPEP 333/4885KMT2A 3322/4885MEN1 1586/4885 |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | ANPEP 881/4885KMT2A 3209/4885MEN1 4127/4885 |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | ITGB1, ITGB2, ITGA2 | ANPEP 881/4885KMT2A 3209/4885MEN1 4127/4885 |
| US-20110082286-A1 | Method for Generating Aptamers with Improved Off-Rates | DDX1, DDX3X, DDX18 | ANPEP 220/4885KMT2A 1608/4885MEN1 4259/4885 |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | ANPEP 2455/4885KMT2A 1548/4885MEN1 1227/4885 |
| US-20240218374-A1 | Nucleic Acid Compounds That Bind Coronavirus Proteins | SARS1, RNGTT, PABPC1 | ANPEP 42/4885KMT2A 3666/4885MEN1 4651/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | ANPEP 3847/4885KMT2A 1449/4885MEN1 3032/4885 |
| US-20230024434-A1 | Methods for Developing Personalized Drug Treatment Plans and Targeted Drug Development Based on Proteomic Profiles | TTR, TPX2, FABP1 | ANPEP 118/4885KMT2A 3305/4885MEN1 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.